<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Aliment Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Aliment. Pharmacol. Ther</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1365-2036</journal-id><journal-id journal-id-type="publisher-id">APT</journal-id><journal-title-group><journal-title>Alimentary Pharmacology &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0269-2813</issn><issn pub-type="epub">1365-2036</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27859410</article-id><article-id pub-id-type="pmc">5215718</article-id><article-id pub-id-type="doi">10.1111/apt.13852</article-id><article-id pub-id-type="publisher-id">APT13852</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Inflammatory Bowel Disease</subject></subj-group></article-categories><title-group><article-title>Effects of vedolizumab on health&#x02010;related quality of life in patients with ulcerative colitis: results from the randomised <styled-content style="fixed-case">GEMINI</styled-content> 1 trial</article-title><alt-title alt-title-type="left-running-head">B. G. Feagan <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="apt13852-cr-0001" contrib-type="author" corresp="yes"><name><surname>Feagan</surname><given-names>B. G.</given-names></name><address><email>brian.feagan@robartsinc.com</email></address><xref ref-type="aff" rid="apt13852-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="apt13852-cr-0002" contrib-type="author"><name><surname>Patel</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="apt13852-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="apt13852-cr-0003" contrib-type="author"><name><surname>Colombel</surname><given-names>J.&#x02010;F.</given-names></name><xref ref-type="aff" rid="apt13852-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="apt13852-cr-0004" contrib-type="author"><name><surname>Rubin</surname><given-names>D. T.</given-names></name><xref ref-type="aff" rid="apt13852-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="apt13852-cr-0005" contrib-type="author"><name><surname>James</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="apt13852-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="apt13852-cr-0006" contrib-type="author"><name><surname>Mody</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="apt13852-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="apt13852-cr-0007" contrib-type="author"><name><surname>Lasch</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="apt13852-aff-0007">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="apt13852-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Robarts Clinical Trials</named-content><named-content content-type="organisation-division">Robarts Research Institute</named-content><institution>University of Western Ontario</institution><named-content content-type="city">London</named-content><named-content content-type="country-part">ON</named-content><country country="CA">Canada</country></aff><aff id="apt13852-aff-0002"><label><sup>2</sup></label><institution>Immensity Consulting, Inc.</institution><named-content content-type="city">Chicago</named-content><named-content content-type="country-part">IL</named-content><country country="US">USA</country></aff><aff id="apt13852-aff-0003"><label><sup>3</sup></label><institution>Icahn School of Medicine at Mount Sinai</institution><named-content content-type="city">New York</named-content><named-content content-type="country-part">NY</named-content><country country="US">USA</country></aff><aff id="apt13852-aff-0004"><label><sup>4</sup></label><institution>University of Chicago Medicine Inflammatory Bowel Disease Center</institution><named-content content-type="city">Chicago</named-content><named-content content-type="country-part">IL</named-content><country country="US">USA</country></aff><aff id="apt13852-aff-0005"><label><sup>5</sup></label><institution>Takeda Development Centre Europe Ltd.</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="apt13852-aff-0006"><label><sup>6</sup></label><institution>Takeda Development Center Americas, Inc.</institution><named-content content-type="city">Deerfield</named-content><named-content content-type="country-part">IL</named-content><country country="US">USA</country></aff><aff id="apt13852-aff-0007"><label><sup>7</sup></label><institution>Takeda Pharmaceuticals USA, Inc.</institution><named-content content-type="city">Deerfield</named-content><named-content content-type="country-part">IL</named-content><country country="US">USA</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold><break/>
Dr B. G. Feagan, Robarts Clinical Trials Inc., 100 Dundas St, Suite 200, London, ON, Canada N6A 5B6.<break/>
E&#x02010;mail: <email>brian.feagan@robartsinc.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2017</year></pub-date><volume>45</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/apt.2017.45.issue-2</issue-id><fpage>264</fpage><lpage>275</lpage><history><date date-type="received"><day>08</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>02</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>20</day><month>9</month><year>2016</year></date><date date-type="rev-recd"><day>10</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. <italic>Alimentary Pharmacology &#x00026; Therapeutics</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:APT-45-264.pdf"/><abstract id="apt13852-abs-0001"><title>Summary</title><sec id="apt13852-sec-0001"><title>Background</title><p>Health&#x02010;related quality of life (<styled-content style="fixed-case">HRQL</styled-content>) is often diminished in patients with ulcerative colitis.</p></sec><sec id="apt13852-sec-0002"><title>Aim</title><p>To evaluate the effects of vedolizumab on <styled-content style="fixed-case">HRQL</styled-content> in patients with ulcerative colitis.</p></sec><sec id="apt13852-sec-0003"><title>Methods</title><p>Using maintenance phase data from the <styled-content style="fixed-case">GEMINI</styled-content> 1 study, an analysis of covariance model was used to calculate mean differences between the vedolizumab and placebo groups in changes from baseline to week 52 for 3 <styled-content style="fixed-case">HRQL</styled-content> instruments: The Inflammatory Bowel Disease Questionnaire (<styled-content style="fixed-case">IBDQ</styled-content>), 36&#x02010;Item Short Form Health Survey (<styled-content style="fixed-case">SF</styled-content>&#x02010;36), and <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D. Proportions of patients meeting minimal clinically important difference (<styled-content style="fixed-case">MCID</styled-content>) thresholds for changes on these instruments were compared between treatment groups for the overall population and for clinically important subgroups. Concordance between clinical remission and remission defined using <styled-content style="fixed-case">IBDQ</styled-content> scores was examined.</p></sec><sec id="apt13852-sec-0004"><title>Results</title><p>Compared with placebo&#x02010;treated patients, vedolizumab&#x02010;treated patients had greater improvements (152&#x02013;201%) in <styled-content style="fixed-case">IBDQ</styled-content>,<styled-content style="fixed-case"> EQ</styled-content>&#x02010;5D visual analogue scale (<styled-content style="fixed-case">VAS</styled-content>), and <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D utility scores. Greater proportions (6.9&#x02013;19.9%) of vedolizumab&#x02010;treated patients than placebo&#x02010;treated patients met <styled-content style="fixed-case">MCID</styled-content> thresholds for all the instruments. Vedolizumab&#x02010;treated patients with lower baseline disease activity and those without prior tumour necrosis factor (<styled-content style="fixed-case">TNF</styled-content>) antagonist failure had greater <styled-content style="fixed-case">HRQL</styled-content> improvements. Among 127 patients with clinical remission based on complete Mayo Clinic scores, &#x0003e;80% also had <styled-content style="fixed-case">IBDQ</styled-content> remission; &#x0003e;70% of the 150 patients with <styled-content style="fixed-case">IBDQ</styled-content> remission demonstrated clinical remission.</p></sec><sec id="apt13852-sec-0005"><title>Conclusions</title><p>Vedolizumab therapy was associated with significant improvements in <styled-content style="fixed-case">HRQL</styled-content> measures compared with placebo. Benefits were greater in patients with lower disease activity and no prior <styled-content style="fixed-case">TNF</styled-content> antagonist failure.</p></sec></abstract><funding-group><award-group><funding-source>Millennium Pharmaceuticals, Inc.</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="5"/><page-count count="12"/><word-count count="8532"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>apt13852</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.0 mode:remove_FC converted:05.01.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="apt13852-ntgp-0001"><fn id="apt13852-note-1001"><p>
<italic>The Handling Editor for this article was Professor Ailsa Hart, and it was accepted for publication after full peer&#x02010;review</italic>.</p></fn></fn-group></notes></front><body><sec id="apt13852-sec-0006"><title>Introduction</title><p>Ulcerative colitis is a chronic inflammatory disease characterised by episodes of active disease interspersed with periods of remission.<xref rid="apt13852-bib-0001" ref-type="ref">1</xref>, <xref rid="apt13852-bib-0002" ref-type="ref">2</xref> Its symptoms, which include rectal bleeding, increased stool frequency, and abdominal cramps, adversely affect health&#x02010;related quality of life (HRQL).<xref rid="apt13852-bib-0001" ref-type="ref">1</xref>, <xref rid="apt13852-bib-0002" ref-type="ref">2</xref> Results from a large European survey indicated that approximately three&#x02010;quarters of patients with ulcerative colitis reported that symptoms interfere with their ability to enjoy leisure activities; almost 70% stated that symptoms negatively affect work performance.<xref rid="apt13852-bib-0003" ref-type="ref">3</xref> Although disease activity is strongly inversely correlated with HRQL as assessed by both generic and disease&#x02010;specific instruments,<xref rid="apt13852-bib-0001" ref-type="ref">1</xref>, <xref rid="apt13852-bib-0002" ref-type="ref">2</xref>, <xref rid="apt13852-bib-0004" ref-type="ref">4</xref>, <xref rid="apt13852-bib-0005" ref-type="ref">5</xref>, <xref rid="apt13852-bib-0006" ref-type="ref">6</xref> it does not fully account for HRQL status; some patients report poor HRQL even during periods of low disease activity.<xref rid="apt13852-bib-0002" ref-type="ref">2</xref>, <xref rid="apt13852-bib-0007" ref-type="ref">7</xref>, <xref rid="apt13852-bib-0008" ref-type="ref">8</xref> Numerous studies have suggested that perceived stress level, anxiety or depression, female sex, coexisting fatigue, and number of relapses are independent determinants of low HRQL in patients with inflammatory bowel disease<xref rid="apt13852-bib-0009" ref-type="ref">9</xref>, <xref rid="apt13852-bib-0010" ref-type="ref">10</xref>, <xref rid="apt13852-bib-0011" ref-type="ref">11</xref>, <xref rid="apt13852-bib-0012" ref-type="ref">12</xref>, <xref rid="apt13852-bib-0013" ref-type="ref">13</xref>, <xref rid="apt13852-bib-0014" ref-type="ref">14</xref>, <xref rid="apt13852-bib-0015" ref-type="ref">15</xref>, <xref rid="apt13852-bib-0016" ref-type="ref">16</xref>; however, this area remains poorly understood.</p><p>Vedolizumab (ENTYVIO; Takeda Pharmaceuticals America, Inc.; Deerfield, IL, USA) is a gut&#x02010;selective anti&#x02010;&#x003b1;<sub>4</sub>&#x003b2;<sub>7</sub> integrin monoclonal antibody that is approved in multiple jurisdictions for treatment of adults with moderately to severely active ulcerative colitis. The efficacy and safety of vedolizumab therapy for ulcerative colitis were established in GEMINI 1, a phase 3, randomised, double&#x02010;blind, placebo&#x02010;controlled #bib52&#x02010;week study with induction and maintenance phases.<xref rid="apt13852-bib-0017" ref-type="ref">17</xref> Although multiple disease&#x02010;specific and generic HRQL instruments were used in GEMINI 1, the effects of vedolizumab therapy on HRQL have not been examined thoroughly. Specifically, the magnitude of HRQL changes for individual instrument domains and data from clinically important subgroups have not been reported.</p><p>Our objectives were to use maintenance phase data from GEMINI 1 to evaluate (i) changes from baseline in HRQL by treatment group using disease&#x02010;specific and generic instruments; (ii) effects of vedolizumab overall and in clinically important subgroups based on disease severity at baseline and prior tumour necrosis factor (TNF) antagonist failure status; (iii) proportions of patients by treatment group with clinically meaningful improvements from baseline in measures of HRQL; and (iv) the degree of concordance between remission as defined by Mayo Clinic scores and remission defined by Inflammatory Bowel Disease Questionnaire (IBDQ) scores and examine potential explanations for discordance between these metrics.</p></sec><sec id="apt13852-sec-0007"><title>Materials and methods</title><sec id="apt13852-sec-0008"><title>Study design</title><p>The methods of GEMINI 1 have been described previously (ClinicalTrials.gov number NCT00783718).<xref rid="apt13852-bib-0017" ref-type="ref">17</xref> The study protocol, all applicable amendments, and informed consent documentation were reviewed and approved by the institutional review board(s) or independent ethics committee(s) at each participating investigational centre. Figure S1 (published online) provides an overview of the study design. Two patient cohorts were screened and enrolled. During the induction phase (weeks 0&#x02013;6), patients in cohort 1 were randomly assigned to receive double&#x02010;blind treatment with vedolizumab 300 mg or placebo at weeks 0 and 2. The second cohort was enrolled to fulfil sample size requirements for the maintenance phase; these patients received open&#x02010;label vedolizumab 300 mg at weeks 0 and 2 during the induction phase. A maintenance phase (weeks 6&#x02013;52) followed, wherein patients from cohorts 1 and 2 with a clinical response to vedolizumab (defined as a reduction in complete Mayo Clinic score of &#x02265;3 points and a decrease of &#x02265;30% from the baseline score with a decrease of &#x02265;1 point on the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1) at week 6 of the induction phase were randomly assigned (1:1:1) to receive placebo, vedolizumab 300 mg every 4 weeks, or vedolizumab 300 mg every 8 weeks. These patients comprised the maintenance intention&#x02010;to&#x02010;treat population. Patients who did not respond to vedolizumab during the induction phase continued to receive vedolizumab 300 mg every 4 weeks during the maintenance phase, and patients who received placebo during the induction phase continued to receive placebo every 4 weeks during the maintenance phase.</p></sec><sec id="apt13852-sec-0009"><title>Health&#x02010;related quality of life assessments</title><p>Health&#x02010;related quality of life was assessed by the IBDQ #bib36&#x02010;Item Short Form Health Survey (SF&#x02010;36), and EQ&#x02010;5D, which were administered at screening (baseline) and before dosing at weeks 6, 30, and 52 and at the early termination visit if applicable. The IBDQ is a 32&#x02010;item, disease&#x02010;specific instrument that has been validated for use in ulcerative colitis<xref rid="apt13852-bib-0018" ref-type="ref">18</xref> and comprises 4 subscales (bowel symptoms, systemic symptoms, social function, and emotional function).<xref rid="apt13852-bib-0019" ref-type="ref">19</xref> Total scores range from 32 to 224 points, with higher scores indicating better HRQL. A total IBDQ score &#x02265;170 points is considered to constitute clinical remission in HRQL terms.<xref rid="apt13852-bib-0002" ref-type="ref">2</xref> The SF&#x02010;36<xref rid="apt13852-bib-0020" ref-type="ref">20</xref> is a generic HRQL measure comprising 36 items that are divided into two summary components (mental component summary and physical component summary) and 8 subscales (physical functioning, role&#x02010;physical, bodily pain, general health, vitality, social functioning, role&#x02010;emotional, and mental health). The EQ&#x02010;5D is a generic HRQL measure that evaluates five dimensions of health status (mobility, self&#x02010;care, usual activities, pain/discomfort, and anxiety/depression) rated on a 3&#x02010;point scale (1, <italic>no problems</italic>; 2, <italic>moderate problems</italic>; 3, <italic>extreme problems</italic>).<xref rid="apt13852-bib-0021" ref-type="ref">21</xref>, <xref rid="apt13852-bib-0022" ref-type="ref">22</xref>, <xref rid="apt13852-bib-0023" ref-type="ref">23</xref> The EQ&#x02010;5D includes a visual analogue scale on which health status is rated from 0 (<italic>worst imaginable</italic>) to 100 (<italic>best imaginable</italic>). EQ&#x02010;5D utility scores were derived on the basis of UK population&#x02010;based preference weights and a previously described scoring algorithm.<xref rid="apt13852-bib-0024" ref-type="ref">24</xref>, <xref rid="apt13852-bib-0025" ref-type="ref">25</xref>
</p></sec><sec id="apt13852-sec-0010"><title>Patient subgroups</title><p>Health&#x02010;related quality of life for each treatment group was assessed for the maintenance intention&#x02010;to&#x02010;treat population overall and for patient subgroups defined by baseline Mayo Clinic score (&#x0003c;9 or &#x02265;9 points) and by prior TNF antagonist failure status.</p></sec><sec id="apt13852-sec-0011"><title>Statistical analyses</title><p>Descriptive statistics were used to summarise patient demographics, baseline characteristics, and concomitant therapy use. All statistical analyses described herein were performed <italic>post hoc</italic>. For scores on the IBDQ (total), IBDQ subscales, SF&#x02010;36 mental component summary and SF&#x02010;36 physical component summary, SF&#x02010;36 subscales, EQ&#x02010;5D visual analogue scale, and EQ&#x02010;5D utility index, adjusted mean changes from baseline to week 52 were calculated for each treatment group using an analysis of covariance model. The mean, standard error, and 95% confidence interval (CI) for differences in mean changes from baseline between each vedolizumab group and the placebo group were also calculated. Missing data were imputed using the last observation carried forward approach. The same methodology was used to evaluate changes from baseline for each HRQL instrument score among patient subgroups defined by baseline Mayo Clinic score and by prior TNF antagonist failure status.</p><p>The SF&#x02010;36 mental component summary and physical component summary scores were normalised to the general US population, with a mean score of 50 points and a standard deviation (s.d.) of 10 points.<xref rid="apt13852-bib-0020" ref-type="ref">20</xref> For each treatment group, means and associated 95% CIs for SF&#x02010;36 mental component summary score, physical component summary score, and each subscale score were calculated for baseline and week 52. Mean scores at week 52 were compared with US population norms. The 95% CI of the US population norm was calculated as 50 &#x000b1; 1.96 &#x000d7; [10/sqrt (<italic>n</italic> for the treatment group)]; if the 95% CI of the mean of the SF&#x02010;36 parameter for the treatment group did not overlap with the 95% CI for the US population norm, the treatment mean was considered significantly different from the US norm.</p><p>For each HRQL instrument, the <italic>minimal clinically important difference threshold</italic> was defined on the basis of published literature as follows: a change of &#x02265;16 points for IBDQ<xref rid="apt13852-bib-0026" ref-type="ref">26</xref>; a change of &#x02265;5 points for both the SF&#x02010;36 mental component summary and SF&#x02010;36 physical component summary<xref rid="apt13852-bib-0027" ref-type="ref">27</xref>; a change of &#x02265;10 points for the EQ&#x02010;5D visual analogue scale<xref rid="apt13852-bib-0027" ref-type="ref">27</xref>; and a change of 0.5 times the population s.d. at baseline for the EQ&#x02010;5D utility index.<xref rid="apt13852-bib-0028" ref-type="ref">28</xref> The number and proportion of patients in each treatment group who met the minimal clinically important difference threshold at week 52 for each HRQL instrument were calculated, as were the number and proportion of patients in each treatment group with a week&#x02010;52 IBDQ total score of &#x02265;170 points. The last observation carried forward approach was used for imputation of missing data before determining whether minimal clinically important difference thresholds were met.</p></sec><sec id="apt13852-sec-0012"><title>Concordance between clinical and IBDQ&#x02010;defined remission</title><p>Concordance between remission as defined by clinical measures and remission as defined by IBDQ scores was calculated. Two definitions of <italic>clinical remission</italic> were used: <italic>complete Mayo Clinic score clinical remission</italic> was defined as a complete Mayo Clinic score &#x02264;2 points and no individual subscore &#x0003e;1 point, and <italic>partial Mayo Clinic score clinical remission</italic> was defined as a partial Mayo Clinic score &#x02264;2 points and no individual subscale score &#x0003e;1 point.<xref rid="apt13852-bib-0029" ref-type="ref">29</xref>
<italic>IBDQ remission</italic> was defined by an IBDQ total score &#x02265;170 points. Missing data were considered as nonremitters in the analyses. Two&#x02010;by&#x02010;two tables displaying concordance and discordance between these measures were generated, along with Kappa statistics to show the strength of agreement. The Kappa statistic can be interpreted as follows: less than chance agreement, &#x0003c;0; slight agreement #bib0.01&#x02013;0.20; fair agreement, 0.21&#x02013;0.40; moderate agreement, 0.41&#x02013;0.60; substantial agreement, 0.61&#x02013;0.80; almost perfect agreement, 0.81&#x02013;0.99.<xref rid="apt13852-bib-0030" ref-type="ref">30</xref>, <xref rid="apt13852-bib-0031" ref-type="ref">31</xref> Differences between the concordant and discordant groups in demographic and other baseline characteristics were examined using descriptive statistics.</p></sec></sec><sec id="apt13852-sec-0013"><title>Results</title><sec id="apt13852-sec-0014"><title>Study patients</title><p>In the GEMINI 1 study, 373 patients were randomly assigned to receive maintenance treatment with placebo (<italic>n</italic> = 126) or 300 mg of vedolizumab every 8 weeks (<italic>n</italic> = 122) or every 4 weeks (<italic>n</italic> = 125).<xref rid="apt13852-bib-0017" ref-type="ref">17</xref> No clinically important differences between groups in demographics, baseline patient characteristics, or concomitant therapies were noted (Table <xref rid="apt13852-tbl-0001" ref-type="table-wrap">1</xref>). For all treatment groups, mean SF&#x02010;36 mental component summary scores at baseline were &#x0003e;10 points below the average for the general US population (i.e. 50 points),<xref rid="apt13852-bib-0020" ref-type="ref">20</xref> whereas mean baseline physical component summary scores were slightly higher. As required by the protocol, all patients had experienced a clinical response over the course of 6 weeks, having received two 300&#x02010;mg infusions of vedolizumab during the induction phase.</p><table-wrap id="apt13852-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics, baseline characteristics, and prior and concomitant therapies</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="top" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 126)<xref ref-type="fn" rid="apt13852-note-0004">a</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 8 weeks (<italic>n</italic> = 122)<xref ref-type="fn" rid="apt13852-note-0005">b</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 4 weeks (<italic>n</italic> = 125)<xref ref-type="fn" rid="apt13852-note-0006">c</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Demographics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, years, mean (s.d.)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">40.3 (14)</td><td align="char" char=" " rowspan="1" colspan="1">41.0 (13)</td><td align="char" char=" " rowspan="1" colspan="1">38.6 (14)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male sex, No. (%)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">69 (55)</td><td align="char" char=" " rowspan="1" colspan="1">70 (57)</td><td align="char" char=" " rowspan="1" colspan="1">68 (54)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current smoker, No. (%)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">8 (6)</td><td align="char" char=" " rowspan="1" colspan="1">7 (6)</td><td align="char" char=" " rowspan="1" colspan="1">8 (6)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Geographic region, No. (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">North America</td><td align="char" char=" " rowspan="1" colspan="1">36 (29)</td><td align="char" char=" " rowspan="1" colspan="1">49 (40)</td><td align="char" char=" " rowspan="1" colspan="1">37 (30)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Western/Northern Europe</td><td align="char" char=" " rowspan="1" colspan="1">20 (16)</td><td align="char" char=" " rowspan="1" colspan="1">23 (19)</td><td align="char" char=" " rowspan="1" colspan="1">25 (20)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Central Europe</td><td align="char" char=" " rowspan="1" colspan="1">26 (21)</td><td align="char" char=" " rowspan="1" colspan="1">20 (16)</td><td align="char" char=" " rowspan="1" colspan="1">25 (20)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Eastern Europe</td><td align="char" char=" " rowspan="1" colspan="1">10 (8)</td><td align="char" char=" " rowspan="1" colspan="1">12 (10)</td><td align="char" char=" " rowspan="1" colspan="1">11 (9)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asia/Australia/Africa</td><td align="char" char=" " rowspan="1" colspan="1">34 (27)</td><td align="char" char=" " rowspan="1" colspan="1">18 (15)</td><td align="char" char=" " rowspan="1" colspan="1">27 (22)</td></tr><tr><td align="left" colspan="4" rowspan="1">Baseline medication use</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Corticosteroid use, No. (%)</td><td align="char" char=" " rowspan="1" colspan="1">72 (57)</td><td align="char" char=" " rowspan="1" colspan="1">70 (57)</td><td align="char" char=" " rowspan="1" colspan="1">73 (58)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Immunomodulator use, No. (%)</td><td align="char" char=" " rowspan="1" colspan="1">51 (40)</td><td align="char" char=" " rowspan="1" colspan="1">43 (35)</td><td align="char" char=" " rowspan="1" colspan="1">45 (36)</td></tr><tr><td align="left" colspan="4" rowspan="1">Disease characteristics</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Duration of disease, years, mean (s.d.)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">7.8 (7)</td><td align="char" char=" " rowspan="1" colspan="1">6.2 (5)</td><td align="char" char=" " rowspan="1" colspan="1">7.6 (7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mayo Clinic score, mean (s.d.)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">8.4 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">8.4 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">8.3 (1.7)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline Mayo Clinic score &#x02265;9, No. (%)</td><td align="char" char=" " rowspan="1" colspan="1">57 (45)</td><td align="char" char=" " rowspan="1" colspan="1">55 (45)</td><td align="char" char=" " rowspan="1" colspan="1">52 (42)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Mayo Clinic endoscopic subscale score, No. (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">0: Normal or inactive disease</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">1: Mild disease</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (&#x0003c;1)<xref ref-type="fn" rid="apt13852-note-0008">e</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">2: Moderate disease</td><td align="char" char=" " rowspan="1" colspan="1">59 (47)</td><td align="char" char=" " rowspan="1" colspan="1">60 (49)</td><td align="char" char=" " rowspan="1" colspan="1">61 (49)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">3: Severe disease</td><td align="char" char=" " rowspan="1" colspan="1">67 (53)</td><td align="char" char=" " rowspan="1" colspan="1">62 (51)</td><td align="char" char=" " rowspan="1" colspan="1">63 (50)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior TNF antagonist failure, No. (%)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">38 (30)</td><td align="char" char=" " rowspan="1" colspan="1">43 (35)</td><td align="char" char=" " rowspan="1" colspan="1">40 (32)</td></tr><tr><td align="left" colspan="4" rowspan="1">HRQL measures</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">IBDQ score, mean (s.d.)<xref ref-type="fn" rid="apt13852-note-0007">d</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline</td><td align="char" char=" " rowspan="1" colspan="1">122 (34)</td><td align="char" char=" " rowspan="1" colspan="1">125 (34)</td><td align="char" char=" " rowspan="1" colspan="1">124 (34)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Week 6<xref ref-type="fn" rid="apt13852-note-0009">f</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">171 (33)</td><td align="char" char=" " rowspan="1" colspan="1">171 (35)</td><td align="char" char=" " rowspan="1" colspan="1">169 (33)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">SF&#x02010;36 physical component summary score, mean (s.d.)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline</td><td align="char" char=" " rowspan="1" colspan="1">39.7 (8.4)</td><td align="char" char=" " rowspan="1" colspan="1">40.0 (8.5)</td><td align="char" char=" " rowspan="1" colspan="1">41.1 (7.7)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Week 6<xref ref-type="fn" rid="apt13852-note-0009">f</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">46.7 (7.8)</td><td align="char" char=" " rowspan="1" colspan="1">47.0 (8.6)</td><td align="char" char=" " rowspan="1" colspan="1">46.8 (7.8)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">SF&#x02010;36 mental component summary score, mean (s.d.)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline</td><td align="char" char=" " rowspan="1" colspan="1">38.5 (12.0)</td><td align="char" char=" " rowspan="1" colspan="1">39.2 (11.6)</td><td align="char" char=" " rowspan="1" colspan="1">37.9 (11.2)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Week 6<xref ref-type="fn" rid="apt13852-note-0009">f</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">45.8 (11.6)</td><td align="char" char=" " rowspan="1" colspan="1">46.0 (12.5)</td><td align="char" char=" " rowspan="1" colspan="1">45.3 (10.5)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">EQ&#x02010;5D visual analogue scale score, mean (s.d.)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline</td><td align="char" char=" " rowspan="1" colspan="1">54.6 (20.2)</td><td align="char" char=" " rowspan="1" colspan="1">56.6 (20.9)</td><td align="char" char=" " rowspan="1" colspan="1">53.6 (20.3)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Week 6<xref ref-type="fn" rid="apt13852-note-0009">f</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">70.5 (18.4)</td><td align="char" char=" " rowspan="1" colspan="1">71.6 (19.9)</td><td align="char" char=" " rowspan="1" colspan="1">70.7 (17.2)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">EQ&#x02010;5D utility score, mean (s.d.)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline</td><td align="char" char=" " rowspan="1" colspan="1">0.677 (0.213)</td><td align="char" char=" " rowspan="1" colspan="1">0.673 (0.235)</td><td align="char" char=" " rowspan="1" colspan="1">0.674 (0.227)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Week 6<xref ref-type="fn" rid="apt13852-note-0009">f</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">0.798 (0.236)</td><td align="char" char=" " rowspan="1" colspan="1">0.799 (0.214)</td><td align="char" char=" " rowspan="1" colspan="1">0.786 (0.200)</td></tr></tbody></table><table-wrap-foot><fn id="apt13852-note-0002"><p>HRQL, health&#x02010;related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; s.d., standard deviation; SF&#x02010;36 #bib36&#x02010;Item Short Form Health Survey; TNF, tumour necrosis factor.</p></fn><fn id="apt13852-note-0003"><p>Patients who received placebo during the randomised maintenance phase had received induction doses of vedolizumab at weeks 0 and 2.</p></fn><fn id="apt13852-note-0004"><label>a</label><p>
<italic>n</italic> = 125 for the baseline EQ&#x02010;5D visual analogue scale score.</p></fn><fn id="apt13852-note-0005"><label>b</label><p>
<italic>n</italic> = 121 for the baseline IBDQ, SF&#x02010;36 physical component summary, SF&#x02010;36 mental component summary, EQ&#x02010;5D visual analogue scale, and EQ&#x02010;5D utility scores.</p></fn><fn id="apt13852-note-0006"><label>c</label><p>
<italic>n</italic> = 124 for baseline IBDQ and <italic>n</italic> = 123 for the baseline SF&#x02010;36 physical component summary, SF&#x02010;36 mental component summary, EQ&#x02010;5D visual analogue scale, and EQ&#x02010;5D utility scores.</p></fn><fn id="apt13852-note-0007"><label>d</label><p>From Feagan <italic>et al</italic>.<xref rid="apt13852-bib-0017" ref-type="ref">17</xref>; also refer to Feagan <italic>et al</italic>. for disease localisation, faecal calprotectin level, and steroid dose.</p></fn><fn id="apt13852-note-0008"><label>e</label><p>This patient from induction cohort 2 had a Mayo Clinic endoscopic subscale score of 1 point and a Mayo Clinic score of 8 points at baseline; therefore, the patient violated the inclusion criteria but was included in the maintenance intention&#x02010;to&#x02010;treat population.</p></fn><fn id="apt13852-note-0009"><label>f</label><p>Week 6 of the study was the first week of the maintenance phase.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="apt13852-sec-0015"><title>Health&#x02010;related quality of life</title><p>By week 52, mean differences from the placebo group in changes from baseline scores on the IBDQ (total and all subscales) and the EQ&#x02010;5D visual analogue scale were statistically significant and generally of similar magnitude for both vedolizumab groups (Table <xref rid="apt13852-tbl-0002" ref-type="table-wrap">2</xref>). For EQ&#x02010;5D utility scores, a significant difference from the placebo group was seen only for the vedolizumab every 4 weeks group (Table <xref rid="apt13852-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="apt13852-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Differences vs. placebo for changes from baseline in disease&#x02010;specific and generic measures of HRQL at week 52</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Instrument</th><th align="center" valign="top" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 126)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 8 weeks (<italic>n</italic> = 122)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 4 weeks (<italic>n</italic> = 125)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IBDQ</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 126</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 121</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 124</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Total</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">122.2 (3.0)</td><td align="char" char=" " rowspan="1" colspan="1">124.5 (3.1)</td><td align="char" char=" " rowspan="1" colspan="1">123.7 (3.1)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">27.3 (3.3)</td><td align="char" char=" " rowspan="1" colspan="1">48.4 (3.4)</td><td align="char" char=" " rowspan="1" colspan="1">49.0 (3.3)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">21.1 (<bold>11.8&#x02013;30.4</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">21.6 (<bold>12.4&#x02013;30.9</bold>)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Bowel systems</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">37.3 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">38.3 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">38.7 (1.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">8.5 (1.1)</td><td align="char" char=" " rowspan="1" colspan="1">17.1 (1.1)</td><td align="char" char=" " rowspan="1" colspan="1">16.3 (1.1)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">8.6 (<bold>5.5&#x02013;11.8</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">7.8 (<bold>4.7&#x02013;10.9</bold>)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Emotional function</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">47.3 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">47.5 (1.3)</td><td align="char" char=" " rowspan="1" colspan="1">47.0 (1.2)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">9.1 (1.2)</td><td align="char" char=" " rowspan="1" colspan="1">16.2 (1.3)</td><td align="char" char=" " rowspan="1" colspan="1">17.0 (1.3)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">7.1 (<bold>3.6&#x02013;10.6</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">7.9 (<bold>4.5&#x02013;11.4</bold>)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Social function</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">19.9 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">20.7 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">20.1 (0.7)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">5.2 (0.6)</td><td align="char" char=" " rowspan="1" colspan="1">7.9 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">8.6 (0.6)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">2.6 (<bold>0.9&#x02013;4.4</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">3.4 (<bold>1.6&#x02013;5.2</bold>)</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Systemic function</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">17.7 (0.5)</td><td align="char" char=" " rowspan="1" colspan="1">18.0 (0.6)</td><td align="char" char=" " rowspan="1" colspan="1">17.9 (0.6)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">4.4 (0.5)</td><td align="char" char=" " rowspan="1" colspan="1">7.3 (0.6)</td><td align="char" char=" " rowspan="1" colspan="1">7.1 (0.5)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">2.9 (<bold>1.4&#x02013;4.4</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">2.7 (<bold>1.2&#x02013;4.2</bold>)</td></tr><tr><td align="left" colspan="4" rowspan="1">EQ&#x02010;5D</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Visual analogue scale</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 125</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 121</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 123</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">54.6 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">56.6 (1.9)</td><td align="char" char=" " rowspan="1" colspan="1">53.6 (1.8)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">9.7 (1.7)</td><td align="char" char=" " rowspan="1" colspan="1">19.0 (1.7)</td><td align="char" char=" " rowspan="1" colspan="1">19.4 (1.7)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">9.3 (<bold>4.6&#x02013;14.0</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">9.7 (<bold>5.0&#x02013;14.4</bold>)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Utility</td><td align="char" rowspan="1" colspan="1">
<italic>n =</italic> 126</td><td align="char" rowspan="1" colspan="1">
<italic>n =</italic> 121</td><td align="char" rowspan="1" colspan="1">
<italic>n =</italic> 123</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Baseline score, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">0.677 (0.019)</td><td align="char" char=" " rowspan="1" colspan="1">0.673 (0.021)</td><td align="char" char=" " rowspan="1" colspan="1">0.674 (0.020)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Adjusted<xref ref-type="fn" rid="apt13852-note-0012">a</xref> change from baseline, mean (S.E.)</td><td align="char" char=" " rowspan="1" colspan="1">0.083 (0.019)</td><td align="char" char=" " rowspan="1" colspan="1">0.131 (0.019)</td><td align="char" char=" " rowspan="1" colspan="1">0.141 (0.019)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Difference from placebo, mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">NA</td><td align="char" char=" " rowspan="1" colspan="1">0.049 (&#x02212;0.003<bold>&#x02013;</bold>0.101)</td><td align="char" char=" " rowspan="1" colspan="1">0.058 (<bold>0.006&#x02013;0.110</bold>)</td></tr></tbody></table><table-wrap-foot><fn id="apt13852-note-0010"><p>CI, confidence interval; HRQL, health&#x02010;related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; NA, not applicable; S.E., standard error.</p></fn><fn id="apt13852-note-0011"><p>Missing data were imputed using the last observation carried forward approach. Bolded 95% CIs indicate significant differences from the placebo group.</p></fn><fn id="apt13852-note-0012"><label>a</label><p>Adjusted mean changes from baseline to week 52 were calculated for each treatment group using an analysis of covariance model.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Among patients with lower baseline disease activity (Mayo Clinic score &#x0003c;9 points), both vedolizumab groups had significantly greater improvements from baseline to week 52 (relative to the placebo group) on all HRQL measures, with the exception of EQ&#x02010;5D utility score (Table <xref rid="apt13852-tbl-0003" ref-type="table-wrap">3</xref>). In patients with higher baseline disease activity (Mayo Clinic score &#x02265;9), the vedolizumab every 8 weeks group, but not the vedolizumab every 4 weeks group, had significantly greater improvements from baseline than the placebo group for all measures of HRQL (Table <xref rid="apt13852-tbl-0003" ref-type="table-wrap">3</xref>). Among patients without prior TNF antagonist failure, improvements from baseline to week 52 on all HRQL measures were significantly greater in both vedolizumab groups than in the placebo group (Table <xref rid="apt13852-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="apt13852-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Differences from placebo for changes in measures of HRQL at week 52 by baseline disease activity</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Instrument Difference from placebo in adjusted<xref ref-type="fn" rid="apt13852-note-0015">a</xref> change from baseline score</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline Mayo Clinic score &#x0003c;9<xref ref-type="fn" rid="apt13852-note-0016">b</xref>
</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Baseline Mayo Clinic score &#x02265;9<xref ref-type="fn" rid="apt13852-note-0017">c</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 8 weeks (<italic>n</italic> = 67)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 4 weeks (<italic>n</italic> = 73)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 8 weeks (<italic>n</italic> = 55)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 4 weeks (<italic>n</italic> = 52)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IBDQ total</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 66</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 73</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 55</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 51</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">20.8 (<bold>8.4&#x02013;33.1</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">27.6 (<bold>15.6&#x02013;39.6</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">21.7 (<bold>7.6&#x02013;35.9</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">13.8 (&#x02212;0.7&#x02013;28.2)</td></tr><tr><td align="left" colspan="5" rowspan="1">SF&#x02010;36</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Physical component summary</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 66</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 73</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 55</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 50</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">2.6 (<bold>0.2&#x02013;5.0</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">3.8 (<bold>1.5&#x02013;6.2</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">4.1 (<bold>1.3&#x02013;6.9</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">1.4 (&#x02212;1.5&#x02013;4.3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mental component summary</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 66</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 73</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 55</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 50</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">5.1 (<bold>1.6&#x02013;8.6</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">6.1 (<bold>2.7&#x02013;9.5</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">4.3 (<bold>0.8&#x02013;7.8</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">2.8 (&#x02212;0.9&#x02013;6.4)</td></tr><tr><td align="left" colspan="5" rowspan="1">EQ&#x02010;5D</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Visual analogue scale</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 66</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 73</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 55</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 50</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">8.2 (<bold>1.7&#x02013;14.6</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">11.5 (<bold>5.3&#x02013;17.8</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">10.5 (<bold>3.4&#x02013;17.5</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">7.2 (0&#x02013;14.5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Utility index</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 66</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 73</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 55</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 50</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">0.007 (&#x02212;0.052&#x02013;0.066)</td><td align="char" char=" " rowspan="1" colspan="1">0.028 (&#x02212;0.029&#x02013;0.086)</td><td align="char" char=" " rowspan="1" colspan="1">0.098 (<bold>0.006&#x02013;0.190</bold>)</td><td align="char" char=" " rowspan="1" colspan="1">0.092 (&#x02212;0.001&#x02013;0.186)</td></tr></tbody></table><table-wrap-foot><fn id="apt13852-note-0013"><p>CI, confidence interval; HRQL, health&#x02010;related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; SF&#x02010;36 #bib36&#x02010;Item Short Form Health Survey.</p></fn><fn id="apt13852-note-0014"><p>Missing data were imputed using the last observation carried forward approach. Bolded 95% CIs indicate significant differences from the placebo group.</p></fn><fn id="apt13852-note-0015"><label>a</label><p>Adjusted mean changes from baseline to week 52 were calculated for each treatment group using an analysis of covariance model.</p></fn><fn id="apt13852-note-0016"><label>b</label><p>
<italic>n</italic> = 69 for the placebo group except for the EQ&#x02010;5D visual analogue scale score (<italic>n</italic> = 68).</p></fn><fn id="apt13852-note-0017"><label>c</label><p>
<italic>n</italic> = 57 for the placebo group.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="apt13852-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Differences from placebo for changes in measures of HRQL at week 52 by prior TNF antagonist failure status</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Instrument Difference from placebo in adjusted<xref ref-type="fn" rid="apt13852-note-0020">a</xref> change from baseline score</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Prior TNF antagonist failure<xref ref-type="fn" rid="apt13852-note-0021">b</xref>
</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">No prior TNF antagonist failure<xref ref-type="fn" rid="apt13852-note-0022">c</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 8 weeks (<italic>n</italic> = 43)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 4 weeks (<italic>n</italic> = 40)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 8 weeks (<italic>n</italic> = 79)</th><th align="center" valign="top" rowspan="1" colspan="1">Vedolizumab every 4 weeks (<italic>n</italic> = 85)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IBDQ total</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 43</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 40</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 78</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 84</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">14.1 (&#x02212;2.5&#x02013;30.7)</td><td align="char" char=" " rowspan="1" colspan="1">13.4 (&#x02212;3.4&#x02013;30.2)</td><td align="char" char="(" rowspan="1" colspan="1">25.9 (<bold>14.6&#x02013;37.3</bold>)</td><td align="char" char="(" rowspan="1" colspan="1">25.8 (<bold>14.7&#x02013;36.9</bold>)</td></tr><tr><td align="left" colspan="5" rowspan="1">SF&#x02010;36</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Physical component summary</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 43</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 40</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 78</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 83</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">2.2 (&#x02212;1.0&#x02013;5.4)</td><td align="char" char=" " rowspan="1" colspan="1">1.1 (&#x02212;2.1&#x02013;4.4)</td><td align="char" char="(" rowspan="1" colspan="1">3.9 (<bold>1.7&#x02013;6.2</bold>)</td><td align="char" char="(" rowspan="1" colspan="1">3.6 (<bold>1.4&#x02013;5.8</bold>)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mental component summary</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 43</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 40</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 78</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 83</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">3.3 (&#x02212;1.2&#x02013;7.8)</td><td align="char" char=" " rowspan="1" colspan="1">2.2 (&#x02212;2.3&#x02013;6.7)</td><td align="char" char="(" rowspan="1" colspan="1">6.0 (<bold>2.9&#x02013;9.0</bold>)</td><td align="char" char="(" rowspan="1" colspan="1">6.2 (<bold>3.2&#x02013;9.1</bold>)</td></tr><tr><td align="left" colspan="5" rowspan="1">EQ&#x02010;5D</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Visual analogue scale</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 43</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 40</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 78</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 83</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">6.8 (&#x02212;1.8&#x02013;15.5)</td><td align="char" char=" " rowspan="1" colspan="1">6.9 (&#x02212;2.0&#x02013;15.7)</td><td align="char" char="(" rowspan="1" colspan="1">10.6 (<bold>4.9&#x02013;16.3</bold>)</td><td align="char" char="(" rowspan="1" colspan="1">11.1 (<bold>5.5&#x02013;16.7</bold>)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Utility index</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 43</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 40</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 78</td><td align="char" rowspan="1" colspan="1">
<italic>n</italic> = 83</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Mean (95% CI)</td><td align="char" char=" " rowspan="1" colspan="1">0.033 (&#x02212;0.073&#x02013;0.139)</td><td align="char" char=" " rowspan="1" colspan="1">0.046 (&#x02212;0.061&#x02013;0.153)</td><td align="char" char="(" rowspan="1" colspan="1">0.062 (<bold>0.003&#x02013;0.120</bold>)</td><td align="char" char="(" rowspan="1" colspan="1">0.066 (<bold>0.008&#x02013;0.123</bold>)</td></tr></tbody></table><table-wrap-foot><fn id="apt13852-note-0018"><p>CI, confidence interval; HRQL, health&#x02010;related quality of life; IBDQ, Inflammatory Bowel Disease Questionnaire; SF&#x02010;36, 36&#x02010;Item Short Form Health Survey; TNF, tumour necrosis factor.</p></fn><fn id="apt13852-note-0019"><p>Missing data were imputed using the last observation carried forward approach. Bolded 95% CIs indicate significant differences from the placebo group.</p></fn><fn id="apt13852-note-0020"><label>a</label><p>Adjusted mean changes from baseline to week 52 were calculated for each treatment group using an analysis of covariance model.</p></fn><fn id="apt13852-note-0021"><label>b</label><p>
<italic>n</italic> = 38 for the placebo group except for the EQ&#x02010;5D visual analogue scale score (<italic>n</italic> = 37).</p></fn><fn id="apt13852-note-0022"><label>c</label><p>
<italic>n</italic> = 88 for the placebo group.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The mean SF&#x02010;36 mental component summary and physical component summary scores for both vedolizumab groups that had responded to induction therapy were similar to US population norms at week 52 (Figure <xref rid="apt13852-fig-0001" ref-type="fig">1</xref>). In contrast, mean scores on both domains were significantly lower than US population norms for patients who had received induction therapy and had subsequently been assigned to receive placebo. General health was the only SF&#x02010;36 subscale on which the mean scores of either vedolizumab group were significantly lower than US population norms; in contrast, mean scores for the placebo group were significantly lower than US population norms for all subscales except physical functioning (Figure S2, published online). Overall, compared with placebo&#x02010;treated patients, patients treated with vedolizumab had 152&#x02013;201% greater improvements in IBDQ, EQ&#x02010;5D visual analogue scale, and EQ&#x02010;5D utility scores.</p><fig fig-type="Figure" xml:lang="en" id="apt13852-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Mean scores at baseline (black portion of the bars) and increases in mean scores at week 52 (grey portion of the bars) for the <styled-content style="fixed-case">SF</styled-content>&#x02010;36 physical component summary and <styled-content style="fixed-case">SF</styled-content>&#x02010;36 mental component summary. Missing data were imputed using the last observation carried forward approach. *Indicates week 52 value that is considered significantly different from the <styled-content style="fixed-case">US</styled-content> population norm (i.e. the 95% <styled-content style="fixed-case">CI</styled-content> of the mean of the <styled-content style="fixed-case">SF</styled-content>&#x02010;36 parameter for the treatment group does not overlap with the 95% <styled-content style="fixed-case">CI</styled-content> of the <styled-content style="fixed-case">US</styled-content> population norm). For all parameters, at baseline: placebo <italic>n</italic> = 126, vedolizumab every 8 weeks <italic>n</italic> = 121, and vedolizumab every 4 weeks <italic>n</italic> = 123; at week 52: placebo <italic>n</italic> = 126, vedolizumab every 8 weeks <italic>n</italic> = 122, and vedolizumab every 4 weeks <italic>n</italic> = 125. Patients who received placebo during the randomised maintenance phase had received induction doses of vedolizumab at weeks 0 and 2. <styled-content style="fixed-case">CI</styled-content>, confidence interval; Q4W, every 4 weeks; Q8W, every 8 weeks; <styled-content style="fixed-case">SF</styled-content>&#x02010;36, 36&#x02010;Item Short&#x02010;Form Health Survey.</p></caption><graphic id="nlm-graphic-1" xlink:href="APT-45-264-g001"/></fig><p>Compared with the placebo group, both vedolizumab groups had significantly greater proportions of patients with an IBDQ total score &#x02265;170 points at week 52 (Figure <xref rid="apt13852-fig-0002" ref-type="fig">2</xref>). The vedolizumab groups had significantly greater proportions of patients who met the minimal clinically important difference thresholds for IBDQ total score (every 8 weeks and every 4 weeks), SF&#x02010;36 physical component summary score (every 8 weeks only), and EQ&#x02010;5D visual analogue scale score (every 8 weeks and every 4 weeks) at week 52 (Figure <xref rid="apt13852-fig-0002" ref-type="fig">2</xref>) than the placebo group did. Overall, the percentage of patients who met minimal clinically important difference thresholds for the IBDQ, SF&#x02010;36 physical component summary scale, SF&#x02010;36 mental component summary scale, EQ&#x02010;5D visual analogue scale, and EQ&#x02010;5D utility score was 6.9&#x02013;19.9% greater with vedolizumab than with placebo.</p><fig fig-type="Figure" xml:lang="en" id="apt13852-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Proportion of patients with <styled-content style="fixed-case">IBDQ</styled-content> total score &#x02265;170 points or with clinically meaningful improvements (i.e. minimal clinically important difference thresholds met) in <styled-content style="fixed-case">HRQL</styled-content> measurements at week 52. Patients who received placebo during the randomised maintenance phase had received induction doses of vedolizumab at weeks 0 and 2. Missing data were imputed using the last observation carried forward approach. *Indicates that a value is considered significantly different from that of placebo (i.e. 95% <styled-content style="fixed-case">CI</styled-content>s for the mean of the difference from placebo do not contain 0). <sup>a</sup>
<italic>n</italic> = 125 for <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D <styled-content style="fixed-case">VAS</styled-content> score. <sup>b</sup>
<italic>n</italic> = 121 for <styled-content style="fixed-case">IBDQ</styled-content> Total minimal clinically important difference, <styled-content style="fixed-case">SF</styled-content>&#x02010;36 mental component summary, <styled-content style="fixed-case">SF</styled-content>&#x02010;36 physical component summary, <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D <styled-content style="fixed-case">VAS</styled-content>, and <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D utility scores. <sup>c</sup>
<italic>n</italic> = 124 for <styled-content style="fixed-case">IBDQ</styled-content> Total minimal clinically important difference; <italic>n</italic> = 123 for <styled-content style="fixed-case">SF</styled-content>&#x02010;36 mental component summary, <styled-content style="fixed-case">SF</styled-content>&#x02010;36 physical component summary, <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D <styled-content style="fixed-case">VAS</styled-content>, and <styled-content style="fixed-case">EQ</styled-content>&#x02010;5D utility scores. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">HRQL</styled-content>, health&#x02010;related quality of life; <styled-content style="fixed-case">IBDQ</styled-content>, Inflammatory Bowel Disease Questionnaire; MCS, mental component summary; PCS, physical component summary; Q4W, every 4 weeks; Q8W, every 8 weeks; <styled-content style="fixed-case">SF</styled-content>&#x02010;36, 36&#x02010;Item Short Form Health Survey; <styled-content style="fixed-case">VAS</styled-content>, visual analogue scale.</p></caption><graphic id="nlm-graphic-3" xlink:href="APT-45-264-g002"/></fig></sec><sec id="apt13852-sec-0016"><title>Concordance between clinical and IBDQ&#x02010;defined remission</title><p>More than 80% of patients with clinical remission at week 52 also had IBDQ remission (108/127 based on complete Mayo Clinic score, 129/159 based on partial Mayo Clinic score). Among the 150 patients with IBDQ remission at week 52, more than 70% had concomitant clinical remission (<italic>n</italic> = 108 based on complete Mayo Clinic score, <italic>n</italic> = 129 based on partial Mayo Clinic score).</p><p>Approximately 84% of patients had concordance between remission defined by both IBDQ and clinical measures (Table <xref rid="apt13852-tbl-0005" ref-type="table-wrap">5</xref>). Concordance with IBDQ remission did not differ substantially (&#x0003c;3%) from clinical remission as defined by either complete or partial Mayo Clinic scores. Kappa statistics showed substantial agreement between IBDQ remission and clinical remission [0.65 (95% CI, 0.57&#x02013;0.73) based on complete Mayo Clinic score; 0.72 (95% CI, 0.65&#x02013;0.79) based on partial Mayo Clinic score]. Although most demographic and baseline characteristics were similar among the concordant and discordant groups, concordance appeared to be more common in males, patients with a disease duration &#x0003c;3 years, and patients with baseline Mayo Clinic scores of 9&#x02013;12 points (data not shown).</p><table-wrap id="apt13852-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Concordance between clinical remission and IBDQ remission at week 52 (intention&#x02010;to&#x02010;treat population, <italic>n</italic> = 373)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">IBDQ remission<xref ref-type="fn" rid="apt13852-note-0025">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Yes</th><th align="center" valign="top" rowspan="1" colspan="1">No</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">(A) Clinical remission (complete Mayo Clinic score)<xref ref-type="fn" rid="apt13852-note-0026">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">108 (29.0%)</td><td align="char" char=" " rowspan="1" colspan="1">19 (5.1%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">42 (11.3%)</td><td align="char" char=" " rowspan="1" colspan="1">204 (54.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Kappa statistic (95% CI)<xref ref-type="fn" rid="apt13852-note-0027">c</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">0.65 (0.57&#x02013;0.73)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">(B) Clinical remission (partial Mayo Clinic score)<xref ref-type="fn" rid="apt13852-note-0028">d</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">129 (34.6%)</td><td align="char" char=" " rowspan="1" colspan="1">30 (8.0%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">21 (5.6%)</td><td align="char" char=" " rowspan="1" colspan="1">193 (51.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Kappa statistic (95% CI)<xref ref-type="fn" rid="apt13852-note-0027">c</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">0.72 (0.65&#x02013;0.79)</td><td align="char" char=" " rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="apt13852-note-0023"><p>CI, confidence interval; IBDQ, Inflammatory Bowel Disease Questionnaire.</p></fn><fn id="apt13852-note-0024"><p>Data are shown as No. (%) of patients.</p></fn><fn id="apt13852-note-0025"><label>a</label><p>
<italic>IBDQ remission</italic> was defined by an IBDQ total score &#x02265;170 points.</p></fn><fn id="apt13852-note-0026"><label>b</label><p>
<italic>Clinical remission</italic> was defined by a complete Mayo Clinic score &#x02264;2 points and no individual subscore &#x0003e;1 point (A).</p></fn><fn id="apt13852-note-0027"><label>c</label><p>Kappa statistics: &#x0003c;0, less than chance agreement; 0.01&#x02013;0.20, slight agreement; 0.21&#x02013;0.40, fair agreement; 0.41&#x02013;0.60, moderate agreement; 0.61&#x02013;0.80, substantial agreement; 0.81&#x02013;0.99, almost perfect agreement.</p></fn><fn id="apt13852-note-0028"><label>d</label><p>
<italic>Clinical remission</italic> was defined by a partial Mayo Clinic score &#x02264;2 points and no individual subscore &#x0003e;1 point (B).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="apt13852-sec-0017"><title>Discussion</title><p>Health&#x02010;related quality of life evaluations are now routinely accepted as outcome measures in clinical trials of new medical therapies for ulcerative colitis. Accordingly, the GEMINI 1 trial used several generic and disease&#x02010;specific HRQL instruments at multiple time points throughout the study. At week 6 (i.e. the first week of the maintenance phase) of GEMINI 1, all participants in the maintenance intention&#x02010;to&#x02010;treat population had demonstrated a clinical response to vedolizumab induction therapy (Table <xref rid="apt13852-tbl-0001" ref-type="table-wrap">1</xref>). Following maintenance randomisation, clinically meaningful and statistically significant improvements in both vedolizumab groups compared with placebo were observed for most HRQL measures. For example, following induction, the mean week&#x02010;6 IBDQ scores for the vedolizumab every 8 weeks and every 4 weeks groups and the placebo group were 171, 169, and 171 points, respectively. At week 52, the corresponding values were 172, 173, and 150 points. Given that a total IBDQ score &#x02265;170 denotes remission, these data indicate that most patients treated with vedolizumab over the longer term can be expected to have improved HRQL. Similarly, although participants&#x02019; week 6 SF&#x02010;36 mental component summary scores were less than US population normative values, patients who continued vedolizumab treatment achieved, on average, normal scores at the end of 52 weeks of therapy, whereas those who received placebo showed minimal improvement.</p><p>These treatment&#x02010;related benefits parallel those observed in clinical outcomes such as remission, response, and mucosal improvement. At one level, this observation is not surprising because clinical disease activity is a major determinant of HRQL in patients with ulcerative colitis<xref rid="apt13852-bib-0001" ref-type="ref">1</xref>, <xref rid="apt13852-bib-0002" ref-type="ref">2</xref>, <xref rid="apt13852-bib-0004" ref-type="ref">4</xref>, <xref rid="apt13852-bib-0005" ref-type="ref">5</xref>, <xref rid="apt13852-bib-0006" ref-type="ref">6</xref>, <xref rid="apt13852-bib-0032" ref-type="ref">32</xref>, <xref rid="apt13852-bib-0033" ref-type="ref">33</xref>; however, ulcerative colitis is a complex disease that may adversely affect patients&#x02019; social life, employment status, and psychological functioning,<xref rid="apt13852-bib-0034" ref-type="ref">34</xref>, <xref rid="apt13852-bib-0035" ref-type="ref">35</xref>, <xref rid="apt13852-bib-0036" ref-type="ref">36</xref> and these domains may not improve after a relatively short course of therapy during a lifetime disease experience. More than 80% concordance was demonstrated between patients in clinical remission and those in IBDQ&#x02010;defined remission, and Kappa statistics supported substantial agreement between the two (Table <xref rid="apt13852-tbl-0005" ref-type="table-wrap">5</xref>). Both discordant patient groups are interesting. Persistence of impaired HRQL in the presence of clinical remission may relate to other covariates such as coexisting depression or socioeconomic status. Unfortunately, this study had limited capacity to assess whether these factors were responsible for discordance. A comparison of demographic and baseline characteristics collected for the trial suggested that concordance was more common among males, patients with shorter disease duration, and those with higher baseline Mayo Clinic scores. These <italic>post hoc</italic> analyses were limited to descriptive statistics but could be useful in hypothesis generation for further research.</p><p>Patients who fail to meet the criteria for clinical remission while in IBDQ&#x02010;defined remission are also of interest. A substantial proportion of this subset of discordance (54.8%) was due to failure to achieve a Mayo Clinic endoscopic score of 0 or 1. This observation further emphasises the need for objective assessment of inflammatory disease activity in guiding therapy for ulcerative colitis given the evolving belief that endoscop&#x02010;ically defined treatment targets are preferable to those based on patient&#x02010;reported outcomes<xref rid="apt13852-bib-0035" ref-type="ref">35</xref>; however #bib35.7% of patients who met endoscopic remission criteria failed to meet patient&#x02010;reported outcome criteria, including bleeding (4.8%) and stool frequency (4.8%) criteria. Persistence of increased stool frequency in the presence of mucosal improvement is a recognised phenomenon that may be due to residual histological inflammation or submucosal fibrosis that results in impaired colonic motility.<xref rid="apt13852-bib-0037" ref-type="ref">37</xref> Further research into possible mechanisms underlying persistently increased stool frequency should be conducted in this population. The persistence of bleeding in patients with endoscopically defined remission is poorly understood and may be due to haemorrhoids or persistent disease beyond the range of the sigmoid colon that was examined.</p><p>Results from the subgroup analyses demonstrated that vedolizumab&#x02010;treated patients with lower disease activity at baseline and those with no prior TNF antagonist failure generally had greater improvements (vs. placebo&#x02010;treated patients) in HRQL. The latter is unsurprising when one considers that patients with prior TNF antagonist failure typically demonstrate an overall poorer response to treatment than do patients with no prior TNF antagonist failure,<xref rid="apt13852-bib-0017" ref-type="ref">17</xref>, <xref rid="apt13852-bib-0038" ref-type="ref">38</xref>, <xref rid="apt13852-bib-0039" ref-type="ref">39</xref> possibly because of prevalent non&#x02010;inflammatory conditions such as stricture and malabsorption, which result from persistent inflammation over a long duration of disease. Currently, little else is known about whether ulcerative colitis therapy differentially affects HRQL among various patient subgroups, and more research is needed. In this regard, we could not confirm results from previous studies that identified female sex as a potential covariate.<xref rid="apt13852-bib-0013" ref-type="ref">13</xref>, <xref rid="apt13852-bib-0014" ref-type="ref">14</xref> Also, we did not collect data to evaluate potential effects of coexistent depression and fatigue or the number of previous relapses.</p><p>Our study had some limitations. First, SF&#x02010;36 data from GEMINI 1, which was an international study, were compared with norms from the US population. Population&#x02010;based norms are useful for assessing whether scores differ from expected values in a reference population, and a similar approach has been employed in previous studies.<xref rid="apt13852-bib-0033" ref-type="ref">33</xref>, <xref rid="apt13852-bib-0040" ref-type="ref">40</xref>, <xref rid="apt13852-bib-0041" ref-type="ref">41</xref> Determining whether SF&#x02010;36 scores for patients from each geographic region differ from population norms in that region would require additional analysis and comparison against normative data for each region of interest. Second, in the current analyses, a change of &#x02265;10 points was used as the minimal clinically important difference threshold for the EQ&#x02010;5D visual analogue scale. Although Coteur <italic>et al</italic>.<xref rid="apt13852-bib-0027" ref-type="ref">27</xref> estimated that the EQ&#x02010;5D visual analogue scale minimal clinically important difference ranges between 4.2 and 14.8, a specific value has not been firmly established. Finally, despite the relatively large size of the trial, limited statistical power was available to identify factors predictive of HRQL improvements following vedolizumab therapy in <italic>post hoc</italic> analyses. In future research, data from larger samples will be needed to evaluate potential predictors.</p></sec><sec id="apt13852-sec-0018"><title>Conclusion</title><p>These analyses indicate that patients with a clinical response to vedolizumab induction therapy have improved HRQL with continued treatment. Further research is needed to identify determinants of HRQL in patients with clinically quiescent disease.</p></sec><sec id="apt13852-sec-0019"><title>Authorship</title><p>
<italic>Guarantor of article</italic>: Brian Feagan.</p><p>
<italic>Author contributions</italic>: Brian Feagan, Haridarshan Patel, Jean&#x02010;Fr&#x000e9;d&#x000e9;ric Colombel, David T. Rubin, Karen Lasch, and Reema Mody contributed to the study design, clinical interpretations, and development of the manuscript. Alexandra James provided statistical analyses.</p><p>All authors approved the final draft of the manuscript for submission.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Figure S1.</bold> GEMINI 1 study design. VDZ doses were 300 mg. <sup>a</sup>Induction doses were administered at weeks 0 and 2. <sup>b</sup>Patients who received PBO during the randomised maintenance phase had received induction doses of VDZ at weeks 0 and 2. PBO, placebo; VDZ, vedolizumab.</p></caption><media xlink:href="APT-45-264-s001.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Figure S2.</bold> Mean scores at baseline (black portion of the bars) and increases in mean scores at week 52 (grey portion of the bars) for SF&#x02010;36 subscales. Missing data were imputed using the last observation carried forward approach. * Indicates week 52 value that is considered significantly different from the US population norm (ie, the 95% CI of the mean of the SF&#x02010;36 parameter for the treatment group does not overlap with the 95% CI of the US population norm). For all parameters, at baseline: placebo n=126, vedolizumab every 8 weeks n=121, and vedolizumab every 4 weeks n=123; at week 52: placebo n=126, vedolizumab every 8 weeks n=122, and vedolizumab every 4 weeks n=125. Patients who received placebo during the randomised maintenance phase had received induction doses of vedolizumab at weeks 0 and 2. CI, confidence interval; Q4W, every 4 weeks; Q8W, every 8 weeks; SF&#x02010;36, 36&#x02010;Item Short Form Health Survey.</p></caption><media xlink:href="APT-45-264-s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="apt13852-sec-0020"><title>Acknowledgments</title><p>We would like to thank Caterina Hatzifoti, PhD, of Takeda Pharmaceuticals International for publication management support.</p><p>
<italic>Declaration of personal interests</italic>: Brian Feagan &#x02212; Consultancy: Abbott/AbbVie, ActoGeniX, Akros, Albireo Pharma, Amgen, Astra Zeneca, Avaxia Biologics Inc., Avir Pharma, Axcan, Baxter Healthcare Corp., Biogen Idec, Boehringer&#x02010;Ingelheim, Bristol&#x02010;Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring Pharma, Roche/Genentech, gICare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, Janssen Biotech (Centocor), JnJ/Janssen, Kyowa Hakko Kirin Co Ltd., Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, VHsquared Ltd., Warner Chilcott, Wyeth, Zealand, Zyngenia; Grant/research support: Abbott/AbbVie, Amgen, Astra Zeneca, Bristol&#x02010;Myers Squibb (BMS), Janssen Biotech (Centocor), JnJ/Janssen, Roche/Genentech, Millennium, Pfizer, Receptos, Santarus, Sanofi, Tillotts, UCB Pharma; Membership (scientific advisory board): Abbott/AbbVie, Amgen, Astra Zeneca, Avaxia Biologics Inc., Bristol&#x02010;Myers Squibb, Celgene, Centocor Inc., Elan/Biogen, Ferring, JnJ/Janssen, Merck, Nestles, Novartis, Novo Nordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, TiGenix, Tillotts Pharma AG, UCB Pharma; Membership (board of directors): Robarts Clinical Trials Inc. Haridarshan Patel &#x02013; Employment: Immensity Consulting, Inc. (which received consulting fees from Takeda). Jean&#x02010;Fr&#x000e9;d&#x000e9;ric Colombel &#x02013; Consultancy/advisory board membership: AbbVie, Amgen, Boehringer&#x02010;Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen and Janssen, Medimmune, Merck &#x00026; Co., Pfizer, Protagonist, Second Genome, Seres, Takeda, Theradiag; Speaker: AbbVie, Ferring, Takeda, Shire; Research support: AbbVie, Janssen and Janssen, Genentech, Takeda; Stock options: Intestinal Biotech Development, Genfit. David T. Rubin &#x02212; Consultancy: AbbVie Inc., Bristol&#x02010;Myers Squibb, Centocor/Janssen Pharmaceuticals, Inc., Cornerstones Health, Inc., Elan Pharmaceuticals, Emmi, Given Imaging, Ironwood, Lifecore Biomedical, LLC, Prometheus Pharmaceuticals, Santarus, Shire, Takeda&#x02010;Millennium, Telsar Pharmaceuticals, UCB Pharma, Vertex Pharmaceuticals, Warner Chilcott. Alexandra James &#x02013; Employment: Takeda Development Centre Europe Ltd. Karen Lasch &#x02013; Employment: Takeda Pharmaceuticals U.S.A., Inc. Reema Mody &#x02013; Employment: Takeda Development Center Americas, Inc., Eli Lilly and Company.</p><p>
<italic>Declaration of funding interests</italic>: The clinical study was funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.). The study was designed and implemented by the GEMINI 1 Steering Committee in collaboration with the sponsor, which held and analysed the data. Medical writing support was provided by Elizabeth Barton, MS, of MedLogix Communications, LLC, and was supported by Takeda Pharmaceuticals International, Inc.</p></ack><ref-list content-type="cited-references" id="apt13852-bibl-0001"><title>References</title><ref id="apt13852-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="apt13852-cit-0001">
<string-name>
<surname>Gibson</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Vaizey</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>CM</given-names>
</string-name>, <italic>et al</italic>
<article-title>Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross&#x02010;sectional, observational study</article-title>. <source>J Crohns Colitis</source>
<year>2014</year>; <volume>8</volume>: <fpage>598</fpage>&#x02013;<lpage>606</lpage>.<pub-id pub-id-type="pmid">24345767</pub-id></mixed-citation></ref><ref id="apt13852-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="apt13852-cit-0002">
<string-name>
<surname>Irvine</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Quality of life of patients with ulcerative colitis: past, present, and future</article-title>. <source>Inflamm Bowel Dis</source>
<year>2008</year>; <volume>14</volume>: <fpage>554</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">17973299</pub-id></mixed-citation></ref><ref id="apt13852-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="apt13852-cit-0003">
<string-name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>R</given-names>
</string-name>. <article-title>Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey</article-title>. <source>J Crohns Colitis</source>
<year>2007</year>; <volume>1</volume>: <fpage>10</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">21172179</pub-id></mixed-citation></ref><ref id="apt13852-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="apt13852-cit-0004">
<string-name>
<surname>Kalafateli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Triantos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Theocharis</surname>
<given-names>G</given-names>
</string-name>, <italic>et al</italic>
<article-title>Health&#x02010;related quality of life in patients with inflammatory bowel disease: a single&#x02010;center experience</article-title>. <source>Ann Gastroenterol</source>
<year>2013</year>; <volume>26</volume>: <fpage>243</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24714279</pub-id></mixed-citation></ref><ref id="apt13852-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="apt13852-cit-0005">
<string-name>
<surname>Kuriyama</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kuwaki</surname>
<given-names>K</given-names>
</string-name>, <italic>et al</italic>
<article-title>Clinical factors that impair health&#x02010;related quality of life in ulcerative colitis patients vary with the disease duration</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<year>2008</year>; <volume>20</volume>: <fpage>634</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">18679065</pub-id></mixed-citation></ref><ref id="apt13852-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="apt13852-cit-0006">
<string-name>
<surname>Lix</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Graff</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>JR</given-names>
</string-name>, <italic>et al</italic>
<article-title>Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>
<year>2008</year>; <volume>14</volume>: <fpage>1575</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">18512245</pub-id></mixed-citation></ref><ref id="apt13852-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="apt13852-cit-0007">
<string-name>
<surname>Casellas</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Barreiro de Acosta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Iglesias</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<year>2012</year>; <volume>24</volume>: <fpage>762</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22517240</pub-id></mixed-citation></ref><ref id="apt13852-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="apt13852-cit-0008">
<string-name>
<surname>Rochelle</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Fidler</surname>
<given-names>H</given-names>
</string-name>. <article-title>The importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn's disease</article-title>. <source>J Health Psychol</source>
<year>2013</year>; <volume>18</volume>: <fpage>972</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23027780</pub-id></mixed-citation></ref><ref id="apt13852-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="apt13852-cit-0009">
<string-name>
<surname>Tabibian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tabibian</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Beckman</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Raffals</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Papadakis</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Kane</surname>
<given-names>SV</given-names>
</string-name>. <article-title>Predictors of health&#x02010;related quality of life and adherence in Crohn's disease and ulcerative colitis: implications for clinical management</article-title>. <source>Dig Dis Sci</source>
<year>2015</year>; <volume>60</volume>: <fpage>1366</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">25559754</pub-id></mixed-citation></ref><ref id="apt13852-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="apt13852-cit-0010">
<string-name>
<surname>van der Have</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van der Aalst</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Kaptein</surname>
<given-names>AA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Determinants of health&#x02010;related quality of life in Crohn's disease: a systematic review and meta&#x02010;analysis</article-title>. <source>J Crohns Colitis</source>
<year>2014</year>; <volume>8</volume>: <fpage>93</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">23746864</pub-id></mixed-citation></ref><ref id="apt13852-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="apt13852-cit-0011">
<string-name>
<surname>Iglesias&#x02010;Rey</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barreiro&#x02010;de Acosta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Caama&#x000f1;o&#x02010;Isorna</surname>
<given-names>F</given-names>
</string-name>, <italic>et al</italic>
<article-title>Psychological factors are associated with changes in the health&#x02010;related quality of life in inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>
<year>2014</year>; <volume>20</volume>: <fpage>92</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">24193152</pub-id></mixed-citation></ref><ref id="apt13852-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="apt13852-cit-0012">
<string-name>
<surname>Kim</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KS</given-names>
</string-name>, <italic>et al</italic>
<article-title>Predictive factors of impaired quality of life in Korean patients with inactive inflammatory bowel disease: association with functional gastrointestinal disorders and mood disorders</article-title>. <source>J Clin Gastroenterol</source>
<year>2013</year>; <volume>47</volume>: <fpage>e38</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">23090047</pub-id></mixed-citation></ref><ref id="apt13852-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="apt13852-cit-0013">
<string-name>
<surname>Moradkhani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Beckman</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Tabibian</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Health&#x02010;related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors</article-title>. <source>J Crohns Colitis</source>
<year>2013</year>; <volume>7</volume>: <fpage>467</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">22884758</pub-id></mixed-citation></ref><ref id="apt13852-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="apt13852-cit-0014">
<string-name>
<surname>Magalh&#x000e3;es</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Castro</surname>
<given-names>FD</given-names>
</string-name>, <string-name>
<surname>Carvalho</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Moreira</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Cotter</surname>
<given-names>J</given-names>
</string-name>. <article-title>Quality of life in patients with inflammatory bowel disease: importance of clinical, demographic and psychosocial factors</article-title>. <source>Arq Gastroenterol</source>
<year>2014</year>; <volume>51</volume>: <fpage>192</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25296078</pub-id></mixed-citation></ref><ref id="apt13852-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="apt13852-cit-0015">
<string-name>
<surname>Zhang</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Hewett</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hemming</surname>
<given-names>J</given-names>
</string-name>, <italic>et al</italic>
<article-title>The influence of depression on quality of life in patients with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>
<year>2013</year>; <volume>19</volume>: <fpage>1732</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23669400</pub-id></mixed-citation></ref><ref id="apt13852-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="apt13852-cit-0016">
<string-name>
<surname>Cohen</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Zo&#x000eb;ga</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>SA</given-names>
</string-name>, <italic>et al</italic>
<article-title>Fatigue is highly associated with poor health&#x02010;related quality of life, disability and depression in newly&#x02010;diagnosed patients with inflammatory bowel disease, independent of disease activity</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2014</year>; <volume>39</volume>: <fpage>811</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">24612278</pub-id></mixed-citation></ref><ref id="apt13852-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="apt13852-cit-0017">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Rutgeerts</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sands</surname>
<given-names>BE</given-names>
</string-name>, <italic>et al</italic>
<article-title>Vedolizumab as induction and maintenance therapy for ulcerative colitis</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>699</fpage>&#x02013;<lpage>710</lpage>.<pub-id pub-id-type="pmid">23964932</pub-id></mixed-citation></ref><ref id="apt13852-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="apt13852-cit-0018">
<string-name>
<surname>Han</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>McColl</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Steen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Barton</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Welfare</surname>
<given-names>MR</given-names>
</string-name>. <article-title>The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England</article-title>. <source>Scand J Gastroenterol</source>
<year>1998</year>; <volume>33</volume>: <fpage>961</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">9759953</pub-id></mixed-citation></ref><ref id="apt13852-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="apt13852-cit-0019">
<string-name>
<surname>Guyatt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Irvine</surname>
<given-names>EJ</given-names>
</string-name>, <italic>et al</italic>
<article-title>A new measure of health status for clinical trials in inflammatory bowel disease</article-title>. <source>Gastroenterology</source>
<year>1989</year>; <volume>96</volume>: <fpage>804</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">2644154</pub-id></mixed-citation></ref><ref id="apt13852-bib-0020"><label>20</label><mixed-citation publication-type="miscellaneous" id="apt13852-cit-0020">
<string-name>
<surname>Ware</surname>
<given-names>JE</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>SF&#x02010;36 health survey update</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.SF-36.org/tools/sf36.shtml">http://www.SF-36.org/tools/sf36.shtml</ext-link> (accessed 21 October 2014).</mixed-citation></ref><ref id="apt13852-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="apt13852-cit-0021">
<string-name>
<surname>K&#x000f6;nig</surname>
<given-names>H&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Ulsh&#x000f6;fer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gregor</surname>
<given-names>M</given-names>
</string-name>, <italic>et al</italic>
<article-title>Validation of the EuroQol questionnaire in patients with inflammatory bowel disease</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<year>2002</year>; <volume>14</volume>: <fpage>1205</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">12439115</pub-id></mixed-citation></ref><ref id="apt13852-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="apt13852-cit-0022">
<string-name>
<surname>Brooks</surname>
<given-names>R</given-names>
</string-name>. <article-title>EuroQol: the current state of play</article-title>. <source>Health Policy</source>
<year>1996</year>; <volume>37</volume>: <fpage>53</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">10158943</pub-id></mixed-citation></ref><ref id="apt13852-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="apt13852-cit-0023">
<collab collab-type="authors">EuroQol Group</collab>
. <article-title>EuroQol&#x02013;a new facility for the measurement of health&#x02010;related quality of life</article-title>. <source>Health Policy</source>
<year>1990</year>; <volume>16</volume>: <fpage>199</fpage>&#x02013;<lpage>208</lpage>.<pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="apt13852-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="apt13852-cit-0024">
<collab collab-type="authors">Agency for Healthcare Research and Quality</collab>
. <article-title>Calculating the U.S. population&#x02010;based EQ&#x02010;5D index score</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ahrq.gov/professionals/clinicians-providers/resources/rice/EQ5Dscore.html-weights">http://www.ahrq.gov/professionals/clinicians-providers/resources/rice/EQ5Dscore.html-weights</ext-link>. Updated August 2005 (accessed 5 January 2015).</mixed-citation></ref><ref id="apt13852-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="apt13852-cit-0025">
<string-name>
<surname>Shaw</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Coons</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>US valuation of the EQ&#x02010;5D health states: development and testing of the D1 valuation model</article-title>. <source>Med Care</source>
<year>2005</year>; <volume>43</volume>: <fpage>203</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">15725977</pub-id></mixed-citation></ref><ref id="apt13852-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="apt13852-cit-0026">
<string-name>
<surname>Irvine</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality&#x02010;of&#x02010;life instrument for adult patients with inflammatory bowel disease</article-title>. <source>J Pediatr Gastroenterol Nutr</source>
<year>1999</year>; <volume>28</volume>: <fpage>S23</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">10204520</pub-id></mixed-citation></ref><ref id="apt13852-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="apt13852-cit-0027">
<string-name>
<surname>Coteur</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Feagan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Keininger</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Kosinski</surname>
<given-names>M</given-names>
</string-name>. <article-title>Evaluation of the meaningfulness of health&#x02010;related quality of life improvements as assessed by the SF&#x02010;36 and the EQ&#x02010;5D VAS in patients with active Crohn's disease</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2009</year>; <volume>29</volume>: <fpage>1032</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">19222413</pub-id></mixed-citation></ref><ref id="apt13852-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="apt13852-cit-0028">
<string-name>
<surname>Norman</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Sloan</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Wyrwich</surname>
<given-names>KW</given-names>
</string-name>. <article-title>Interpretation of changes in health&#x02010;related quality of life: the remarkable universality of half a standard deviation</article-title>. <source>Med Care</source>
<year>2003</year>; <volume>41</volume>: <fpage>582</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">12719681</pub-id></mixed-citation></ref><ref id="apt13852-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="apt13852-cit-0029">
<string-name>
<surname>Travis</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Higgins</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Orchard</surname>
<given-names>T</given-names>
</string-name>, <italic>et al</italic>
<article-title>Review article: defining remission in ulcerative colitis</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2011</year>; <volume>34</volume>: <fpage>113</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">21615435</pub-id></mixed-citation></ref><ref id="apt13852-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="apt13852-cit-0030">
<string-name>
<surname>Cohen</surname>
<given-names>J</given-names>
</string-name>. <article-title>A coefficient of agreement for nominal scales</article-title>. <source>Educ Psychol Meas</source>
<year>1960</year>; <volume>20</volume>: <fpage>37</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="apt13852-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="apt13852-cit-0031">
<string-name>
<surname>Landis</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>GG</given-names>
</string-name>. <article-title>The measurement of observer agreement for categorical data</article-title>. <source>Biometrics</source>
<year>1977</year>; <volume>33</volume>: <fpage>159</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">843571</pub-id></mixed-citation></ref><ref id="apt13852-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="apt13852-cit-0032">
<string-name>
<surname>Hodgkins</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yarlas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Karlstadt</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kane</surname>
<given-names>S</given-names>
</string-name>. <article-title>Impact of MMX<sup>&#x000ae;</sup> mesalamine on improvement and maintenance of health&#x02010;related quality of life in patients with ulcerative colitis</article-title>. <source>Inflamm Bowel Dis</source>
<year>2013</year>; <volume>19</volume>: <fpage>386</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">22648999</pub-id></mixed-citation></ref><ref id="apt13852-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="apt13852-cit-0033">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Reinisch</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Rutgeerts</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>The effects of infliximab therapy on health&#x02010;related quality of life in ulcerative colitis patients</article-title>. <source>Am J Gastroenterol</source>
<year>2007</year>; <volume>102</volume>: <fpage>794</fpage>&#x02013;<lpage>802</lpage>.<pub-id pub-id-type="pmid">17324131</pub-id></mixed-citation></ref><ref id="apt13852-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="apt13852-cit-0034">
<string-name>
<surname>Jedel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hood</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Keshavarzian</surname>
<given-names>A</given-names>
</string-name>. <article-title>Getting personal: a review of sexual functioning, body image, and their impact on quality of life in patients with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>
<year>2015</year>; <volume>21</volume>: <fpage>923</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">25789923</pub-id></mixed-citation></ref><ref id="apt13852-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="apt13852-cit-0035">
<string-name>
<surname>Peyrin&#x02010;Biroulet</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sands</surname>
<given-names>BE</given-names>
</string-name>, <italic>et al</italic>
<article-title>Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat&#x02010;to&#x02010;target</article-title>. <source>Am J Gastroenterol</source>
<year>2015</year>; <volume>110</volume>: <fpage>1324</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">26303131</pub-id></mixed-citation></ref><ref id="apt13852-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="apt13852-cit-0036">
<string-name>
<surname>Reiss</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>. <article-title>The role of psychosocial care in adapting to health care reform</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2015</year>; <volume>13</volume>: <fpage>2219</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">26589873</pub-id></mixed-citation></ref><ref id="apt13852-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="apt13852-cit-0037">
<string-name>
<surname>Jharap</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Reinisch</surname>
<given-names>W</given-names>
</string-name>, <italic>et al</italic>
<article-title>Randomised clinical study: discrepancies between patient&#x02010;reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2015</year>; <volume>42</volume>: <fpage>1082</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">26381802</pub-id></mixed-citation></ref><ref id="apt13852-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="apt13852-cit-0038">
<string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Rutgeerts</surname>
<given-names>P</given-names>
</string-name>, <italic>et al</italic>
<article-title>Vedolizumab as induction and maintenance therapy for Crohn's disease</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>711</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">23964933</pub-id></mixed-citation></ref><ref id="apt13852-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="apt13852-cit-0039">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Gasink</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lang</surname>
<given-names>Y</given-names>
</string-name>, <italic>et al</italic>
<article-title>Ustekinumab induction therapy for Crohn's disease refractory to conventional tumor necrosis factor antagonist therapy</article-title>. <source>N Engl J Med</source>. in press.</mixed-citation></ref><ref id="apt13852-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="apt13852-cit-0040">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Sandborn</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Hass</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Niecko</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>J</given-names>
</string-name>. <article-title>Health&#x02010;related quality of life during natalizumab maintenance therapy for Crohn's disease</article-title>. <source>Am J Gastroenterol</source>
<year>2007</year>; <volume>102</volume>: <fpage>2737</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">18042106</pub-id></mixed-citation></ref><ref id="apt13852-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="apt13852-cit-0041">
<string-name>
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Coteur</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Keininger</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Schreiber</surname>
<given-names>S</given-names>
</string-name>. <article-title>Clinically meaningful improvement in health&#x02010;related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease</article-title>. <source>Am J Gastroenterol</source>
<year>2009</year>; <volume>104</volume>: <fpage>1976</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">19471252</pub-id></mixed-citation></ref></ref-list></back></article>